Johnson & Johnson says its single-dose vaccine is 72 per cent effective in preventing COVID-19 in the United States but a lower rate of 66 per cent was observed globally in the large trial conducted across three continents and against multiple variants.
J&J’s main study goal was the prevention of moderate to severe COVID-19, and the vaccine was 85 per cent effective in stopping severe disease and preventing hospitalisation across all geographies and against multiple variants 28 days after immunisation.That level of prevention “will potentially protect hundreds of millions of people from serious and fatal outcomes of COVID-19,” Dr Paul Stoffels, J&J’s chief scientific officer, said in a statement.
Unlike the Pfizer/BioNTech and Moderna vaccines, J&J’s does not require a second shot weeks after the first or need to be kept frozen, making it a strong candidate for use in parts of the world with weak transportation infrastructure and insufficient cold storage facilities.Several studies have emerged this month showing that a South African variant of the coronavirus has mutated in areas of the virus that are key targets of vaccines, reducing their efficacy.
A mid-stage trial of a Novovax Inc coronavirus vaccine in South Africa also showed lower efficacy in the country. It proved to be 60 per cent effective among volunteers who didn’t have HIV. In a separate, late-stage trial in the UK, the vaccine was 89.3 per cent effective.
Source: News Formal (newsformal.com)
People need to know how evil the EU really is..
You’re claiming that the AstraZeneca vaccine has been approved in the EU. This is false. The press briefing has been postponed to 1630 CET.
Why can’t we grab 100% effective one and made in Australia?